Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BridgeBio Pharma's Debt-to-Equity or its related term are showing as below:
FRA:2CL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.5 Med: -1.23 Max: 8.56
Current: -1.09
During the past 9 years, the highest Debt-to-Equity Ratio of BridgeBio Pharma was 8.56. The lowest was -3.50. And the median was -1.23.
FRA:2CL's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16
vs FRA:2CL: -1.09
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
BridgeBio Pharma Debt-to-Equity Related Terms
BridgeBio Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for BridgeBio Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2CL vs ASND, JAZZ, EXEL: Debt-to-Equity Comparison
For the Biotechnology subindustry, BridgeBio Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (FRA:2CL) has a Debt-to-Equity of -1.09 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BridgeBio Pharma and its competitors. According to the industry distribution chart, BridgeBio Pharma ranks #999999 out of 965 companies in the Biotechnology industry.
Is BridgeBio Pharma's Debt-to-Equity too high?
BridgeBio Pharma's current Debt-to-Equity is -1.09. Based on the distribution chart, BridgeBio Pharma ranks #999999 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BridgeBio Pharma has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Debt-to-Equity compare to ASND and JAZZ?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #999999 out of 965 companies for Debt-to-Equity. This places BridgeBio Pharma in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on BridgeBio Pharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Pharma's current Debt-to-Equity is -1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €130.44, compared to a current price of €72.24 — trading 44.6% below its estimated fair value. The current Debt-to-Equity is -1.09. BridgeBio Pharma's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Debt-to-Equity is -1.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?
Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued.
The current stock price of €72.24 is trading 44.6% below its estimated GF Value™ of €130.44.
GuruFocus considers BridgeBio Pharma to be Possible Value Trap.
Key valuation signals for FRA:2CL:
Debt-to-Equity: -1.09
GF Value™: €130.44 vs. price of €72.24 (44.6% below fair value)
No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
73GF Score
Get the complete analysis for FRA:2CL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CL has been successfully added to your 
